ACP does not support NQF measure #2600: “Tobacco Use Screening and Follow-up for People with Serious Mental Illness or Alcohol or Other Drug Dependence.” While this measure represents an important clinical concept and patients diagnosed with schizophrenia should be screened for tobacco use, we note several flaws in the specifications and developers do not cite sufficient evidence to form the basis of the measure. First, the specifications should include some element of risk-adjustment. Treatment success is likely to be confounded by the mental illness. Second, it’s complicated to combine tobacco use with other drug dependence and alcohol dependence because the efficacy of treatment varies by disorder. Third, the specifications do not account for pharmacotherapy options that may be as effective as counseling in managing alcohol- and drug-use disorders. And finally, specifications should include exclusion criteria for patient refusal and patients with limited life expectancy.